San Diego-based Aethlon Medical Inc. and its diagnostic subsidiary, Exosome Sciences Inc. announced that their researchers have developed and initially validated a diagnostic platform that could identify the presence of cancer in analyzed blood samples.

The test could detect the presence of glioblastoma, metastatic melanoma, breast cancer, ovarian cancer, colorectal cancer and pancreatic cancer. Beyond the potential implications in diagnosing cancer, Exosome Science (ESI) researchers believe the high-sensitivity of the platform will allow for effective monitoring of cancer progression and response to corresponding therapies.

“I am immensely proud of the ESI research team as their considerable breadth of collected data reinforces the possibility that a single platform could detect and monitor a wide-range of disease conditions,” said Aethlon Medical CEO Jim Joyce, who also serves as executive chairman at ESI.

Aethlon develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.

For information on validation studies, click here.